# Reduced retinal microvascular density in patients with mixed connective tissue disease: an exploratory pilot study on the interplay between aging, renal function, and complement system

**Authors:** Paola Triggianese, Eugenio Capparelli, Arianna D’Antonio, Carolina Nesi, Marco Lombardo, Barbara Kroegler, Alberto Bergamini, Raffaele Mancino, Anna Paola Mitterhofer, David Della-Morte, Carlo Nucci, Massimo Cesareo, Alessio Martucci

PMC · DOI: 10.3389/fimmu.2026.1724780 · Frontiers in Immunology · 2026-02-05

## TL;DR

This study finds that patients with mixed connective tissue disease have reduced retinal blood vessel density, which may be linked to disease duration, kidney function, and immune system markers.

## Contribution

The study is the first to explore retinal microvascular changes in mixed connective tissue disease using OCT-A.

## Key findings

- Patients with MCTD showed significantly reduced retinal vessel density compared to healthy controls.
- Deep retinal vessel density correlated inversely with disease duration and directly with kidney function.
- Nailfold videocapillaroscopy abnormalities were common in MCTD but not linked to retinal findings.

## Abstract

Mixed connective tissue disease (MCTD) is a systemic autoimmune disease with overlapping features with systemic lupus erythematosus, systemic sclerosis, and inflammatory idiopathic myopathies, characterized by anti-U1-RNP antibodies. Although subclinical retinal microvascular changes have been described in other connective tissue diseases, such data are lacking in patients with MCTD.

We performed a cross-sectional exploratory pilot study including patients with a defined diagnosis of MCTD according to one of the sets of classification criteria and age- and sex-matched healthy controls (HC), with elderly individuals equally distributed. Data on disease duration, renal function (creatinine and eGFR), and complement levels (C3 and C4) were recorded. All participants underwent optical coherence tomography angiography (OCT-A) to evaluate retinal vessel density (VD) using parafoveal, perifoveal, and foveal scans, whole images, and foveal avascular zones (FAZs). Nailfold videocapillaroscopy (NVC) was performed in patients with MCTD on four fingers of both hands to assess microangiopathy patterns.

Patients with MCTD (n = 20, mean age 60.6 ± 11.4 years, 85% females) showed a significant reduction in both superficial and deep retinal VD across all evaluated regions compared with 20 HC. In patients with MCTD, deep retinal VD was inversely correlated with disease duration (r = −0.6, P = 0.0003) and directly correlated with eGFR (r = 0.4, P = 0.05). In patients with MCTD, C3 levels were positively correlated with age (r = 0.4, P = 0.03) and superficial parafoveal VD (r = 0.5, P = 0.008). In MCTD, NVC abnormalities, including non-specific microangiopathy and scleroderma patterns, occurred in 60% (n = 12) of cases and did not correlated with OCT-A findings.

Patients with MCTD present subclinical retinal microvascular abnormalities detectable by OCT-A. Our hypothesis-generating study suggests that retinal vascular changes may be linked to disease duration, renal function, and complement levels. OCT-A may be a useful tool for assessing MCTD.

## Linked entities

- **Diseases:** Mixed connective tissue disease (MONDO:0005854), systemic lupus erythematosus (MONDO:0007915), systemic sclerosis (MONDO:0005100)

## Full-text entities

- **Genes:** PLXNA2 (plexin A2) [NCBI Gene 5362] {aka OCT, PLXN2}, TRIM21 (tripartite motif containing 21) [NCBI Gene 6737] {aka RNF81, RO52, Ro/SSA, SSA, SSA1, TRIM21/Ro52}, SNRNP70 (small nuclear ribonucleoprotein U1 subunit 70) [NCBI Gene 6625] {aka RNPU1Z, RPU1, SNRP70, Snp1, U1-70K, U170K}, SSB (small RNA binding exonuclease protection factor La) [NCBI Gene 6741] {aka LARP3, La, La/SSB, SSB/La}, RO60 (Ro60, Y RNA binding protein) [NCBI Gene 6738] {aka RORNP, SSA2, TROVE2}
- **Diseases:** vasculopathy (MESH:D000090122), VD (MESH:C536223), neoplasia (MESH:D009369), abnormalities in lung and esophageal function (MESH:D008171), microangiopathy (MESH:D014652), diabetes (MESH:D003920), trigeminal neuropathy (MESH:D020433), edema (MESH:D004487), CKD (MESH:D051436), cardiovascular and autoimmune-mediated inflammation (MESH:D007249), HC (MESH:D000067329), autoimmune systemic diseases (MESH:D020274), decline in kidney function (MESH:D007680), SLE (MESH:D008180), MCTD (MESH:D008947), PM/DM (MESH:D003882), SSc (MESH:D012595), polyserositis (MESH:D010505), lymphadenopathy (MESH:D008206), OS (MESH:D000080445), autoimmune disease (MESH:D001327), fingers (MESH:D005383), idiopathic inflammatory myopathies (MESH:D009220), NS (MESH:D056770), retinopathy (MESH:D058437), UIP (MESH:D054990), skin thickening (MESH:D013585), retinal involvement (MESH:D012173), aseptic meningitis (MESH:D008582), vascular damage (MESH:D057772), arthralgia (MESH:D018771), IIM (MESH:D056728), UCTD (MESH:D000074079), polyarthritis (MESH:D001168), GGO (MESH:C000721427), ENA (MESH:C535887), NVC abnormalities (MESH:D000014), Microvascular abnormalities (MESH:D017566), retinal vasculitis (MESH:D031300), CTDs (MESH:D003240), hypertension (MESH:D006973), artery occlusions (MESH:D001157), systemic vasculopathy (MESH:C566007), atherosclerotic cardiovascular diseases (MESH:D050197), PAH (MESH:D000081029), ocular diseases (MESH:D005128), migraine (MESH:D008881), systemic disorders (MESH:D009422), chronic diseases (MESH:D002908), abnormal renal function (MESH:D007674), glaucoma (MESH:D005901), ILD (MESH:D017563), microangiopathic abnormalities (MESH:D000743), retinal microvascular abnormalities (MESH:D012164), ground (MESH:D007815), system (MESH:D015619), RP (MESH:D011928)
- **Chemicals:** ketone (MESH:D007659), urobilinogen (MESH:D014558), nitrite (MESH:D009573), OCT-A (-), creatinine (MESH:D003404), glucose (MESH:D005947), steroid (MESH:D013256), prednisone (MESH:D011241)
- **Species:** Homo sapiens (human, species) [taxon 9606], Enterovirus C (no rank) [taxon 138950]
- **Cell lines:** HEp-2 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_1906)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12916619/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12916619/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC12916619/full.md

---
Source: https://tomesphere.com/paper/PMC12916619